Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cancer Letters

• Publication date

  2018-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.canlet.2017.09.053PMID 29069577
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer?

  2017cited by this paper
• 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells

  2016cited by this paper
• PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).

  2016cited by this paper
• The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches.

  2016cited by this paper
• Harnessing Fluorine–Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs

  2016cited by this paper
• Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms

  2014cited by this paper
• Assessing the clinical utility of cancer genomic and proteomic data across tumor types

  2014cited by this paper
• Discovery and saturation analysis of cancer genes across 21 tumor types

  2014cited by this paper
• New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity

  2014cited by this paper
• Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences

  2014cited by this paper
• Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin.

  2014cited by this paper
• TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

  2014cited by this paper
• Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

  2014cited by this paper
• Comparison of software packages for detecting differential expression in RNA-seq studies

  2013cited by this paper
• The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote

  2013cited by this paper
• More targets, more pathways and more clues for mutant p53

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• Targeted therapy for triple‐negative breast cancer: Where are we?

  2012cited by this paper
• The clonal and mutational evolution spectrum of primary triple-negative breast cancers

  2012cited by this paper
• Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.

  2012cited by this paper
• p53 and its mutants in tumor cell migration and invasion

  2011cited by this paper
• PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53

  2011cited by this paper
• Multiple stress signals activate mutant p53 in vivo.

  2011cited by this paper
• APR‐246 exhibits anti‐leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells

  2011cited by this paper
• Drug combination studies and their synergy quantification using the Chou-Talalay method.

  2010cited by this paper
• Gene ontology analysis for RNA-seq: accounting for selection bias

  2010cited by this paper
• A scaling normalization method for differential expression analysis of RNA-seq data

  2010cited by this paper
• Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis

  2010cited by this paper
• PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.

  2009cited by this paper
• Open Access Method

  2009cited by this paper
• In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249.

  2008cited by this paper
• Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells.

  2007cited by this paper
• PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis

  2005cited by this paper
• Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments

  2004cited by this paper
• Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database.

  2002cited by this paper
• Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

  2002cited by this paper
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995cited by this paper

• TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a 3 comprehensive overview of targeted approaches

  2026cites this paper
• Gambogic acid restores wild-type-like p53 functions to induce ferroptosis in mutant p53 cancer cells

  2025cites this paper
• Cellular activity upregulation of the thermolabile p53 cancer mutant Y220C by small molecule indazole derivatives

  2025cites this paper
• PK11007 Covalently Inhibits Thioredoxin Reductase 1 to Induce Oxidative Stress and Autophagy Impairment in NSCLC Cells

  2025cites this paper
• Exploring Prima-1MET as a single agent or in combination with tamoxifen in breast cancer cells in vitro.

  2025cites this paper
• Cell membrane vaccine delivery system: A review of the recent advances against breast cancer.

  2025cites this paper
• New Treatment Approaches for Triple-Negative Breast Cancer.

  2025cites this paper
• RNA Editing-Mediated Correction of TP53 Nonsense Mutations via Lipid Nanoparticle-Delivered Circular ADAR-Recruiting RNAs.

  2025cites this paper
• GD3 synthase drives resistance to p53-induced apoptosis in breast cancer by modulating mitochondrial function

  2025cites this paper
• Comparative In Silico and In Vitro Studies of Novel Zinc/Tin Metal Coordinates Bearing BRCA-1 Mimetics on Wtp53 and Mtp53 Proteins.

  2025cites this paper
• TP53 Mutation-Specific Dysregulation of Store-Operated Calcium Entry and Apoptotic Sensitivity in Triple-Negative Breast Cancer

  2025cites this paper
• Ferroptosis as a promising targeted therapy for triple negative breast cancer

  2024cites this paper
• Emerging Role of the p53 Pathway in Modulating Natural Killer Cell Mediated Immunity.

  2024cites this paper
• Understanding the prion-like behavior of mutant p53 proteins in triple-negative breast cancer pathogenesis: The current therapeutic strategies and future directions

  2024cites this paper
• TP53R175H mutation promotes breast cancer cell proliferation through CORO1A-P38 MAPK pathway regulation.

  2024cites this paper
• Survivin and p53 expression in benign and malignant lesions of breast

  2023cites this paper
• Prenylated chromones and flavonoids isolated from the roots of Flemingia macrophylla and their anti-lung cancer activity

  2023cites this paper
• Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer

  2023cites this paper
• Transdermal delivery of brucine-encapsulated liposomes significantly enhances anti-tumor outcomes in treating triple-negative breast cancer.

  2023cites this paper
• Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects

  2023cites this paper
• Role of p53 in breast cancer progression: An insight into p53 targeted therapy

  2023cites this paper
• Genetic algorithm-de novo, molecular dynamics and MMGBSA based modelling of a novel Benz-pyrazole based anticancer ligand to functionally revert mutant P53 into wild type P53

  2023cites this paper
• Targeting p53 pathways: mechanisms, structures and advances in therapy

  2023cites this paper
• Triple-Negative Breast Cancer: the Current Aspects of Pathogenesis and Therapies

  2022cites this paper
• Racial disparities in breast cancer preclinical and clinical models

  2022cites this paper
• Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies

  2022cites this paper
• p53 and Zinc: A Malleable Relationship

  2022cites this paper
• Mutant Phenotype p53 Immunohistochemical Expression Is Associated With Poor Prognostic Parameters and Disease-Free Survival in Triple-Negative Metaplastic Breast Carcinoma

  2021influential citation
• The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV

  2021cites this paper
• Upregulation of p53 by tannic acid treatment suppresses the proliferation of human colorectal carcinoma

  2021cites this paper
• IMMUNOHISTOCHEMICAL EXPRESSION OF P53 IN INVASIVE DUCTAL CARCINOMA OF BREAST IN PAKISTANI WOMEN

  2021cites this paper
• Triple Negative Breast Cancer

  2021cites this paper
• Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition

  2021cites this paper
• Palmatine Modulates Triple Negative Mammary Carcinoma by Regulating the Endogenous Function of p53, p21 and Mdm2

  2021cites this paper
• Allicin induces cell cycle arrest and apoptosis of breast cancer cells in vitro via modulating the p53 pathway

  2021cites this paper
• Chronotherapy for the p53 system under DNA damage response

  2021cites this paper
• Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant p53 Isoforms

  2021cites this paper
• Triple Negative Breast Cancer in the Era of miRNA.

  2020cites this paper
• Small Molecules Targeting Mutant P53: A Promising Approach For Cancer Treatment.

  2020cites this paper
• Targeting Itch/p73 pathway by thymoquinone as a novel therapeutic strategy for cancers with p53 mutation

  2020cites this paper
• The Alterations of Cellular Signaling Pathways in the Host Cell upon the High Pathogenic Coronaviruses Infection, SARS-CoV and MERS-CoV. What Could Be Expected from the SARS-CoV-2?

  2020cites this paper
• Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer.

  2020cites this paper
• Assessing the Anti-cancer Therapeutic Mechanism of a Herbal Combination for Breast Cancer on System-level by a Network Pharmacological Approach

  2020cites this paper
• Dietary Flavonoids in p53—Mediated Immune Dysfunctions Linking to Cancer Prevention

  2020cites this paper
• Targeting p53 for the treatment of cancer.

  2020cites this paper
• Recent Synthetic Approaches towards Small Molecule Reactivators of p53

  2020cites this paper
• Follow the Mutations: Toward Class-Specific, Small-Molecule Reactivation of p53

  2020cites this paper
• Novel Aspects of Genetics, Molecular Biology and Clinical Oncology of Sarcomas.

  2020cites this paper
• Deconvolution of the Genomic and Epigenomic Interaction Landscape of Triple-Negative Breast Cancer

  2019cites this paper
• PRIMA-1MET Induces Cellular Senescence and Apoptotic Cell Death in Cholangiocarcinoma Cells

  2019cites this paper
• COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells

  2019cites this paper
• C2-Ceramide-Induced Rb-Dominant Senescence-Like Phenotype Leads to Human Breast Cancer MCF-7 Escape from p53-Dependent Cell Death

  2019cites this paper
• Benzothiazole derivative bearing amide moiety induces p53-mediated apoptosis in HPV16 positive cervical cancer cells

  2019cites this paper
• Emerging roles of aerobic glycolysis in breast cancer

  2019cites this paper
• The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients

  2019cites this paper
• Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma

  2019cites this paper
• Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms

  2019cites this paper
• Anticancer activity of palladium-based complexes against triple-negative breast cancer.

  2019cites this paper
• 18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients

  2018cites this paper
• Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations

  2018cites this paper
• Restoring guardianship of the genome: Anticancer drug strategies to reverse oncogenic mutant p53 misfolding.

  2018cites this paper
• The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells

  2018influential citation
• Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer

  2018cites this paper
• Mutant p53 in breast cancer: potential as a therapeutic target and biomarker

  2018cites this paper